Donga-ST and Kwangdong Pharmaceutical jointly held a ceremony to promote Contrave, a weight loss medicine made by Orexigen Therapeutics, Donga-ST said Friday.

Contrave, sold by Kwangdong in Korea since 2016, is a FDA-approved weight-loss medication working on two areas of the brain—the hunger center and the reward system—to reduce hunger and help control cravings.

Donga-ST _동아ST signed a contract with Kwangdong _광동제약 in August to jointly sell the medicine.

The two companies will start sales and marketing of Contrave for general hospitals from Sep. 1.

The ceremony was attended by Donga-ST CEO Min Jang-sung _민장성, Kwangdong Vice President Ki Young-duk _기영덕 and officials of the two companies.

The event aimed to strengthen cooperation between the two firms and to set sales goals before the launch of co-promotion activities. It also included lectures on obesity-related diseases, and marketing.

Contrave topped the market share in North America with sales of about $127 million in 2016, thanks to strong efficacy and safety with long-term prescription for non-aromatized medicines.

Korea’s obesity treatment market is estimated to be about 90 billion won ($79 million), with the prevalence of obesity steadily increasing.

“We hope to create synergy between the two companies based on the systematic cooperation,” a Donga-ST official said. “We will grow Contrave into a blockbuster product based on the company’s know-how accumulated over excellent sales force in chronic disease treatment products.